Maze Therapeutics Insider Sells 72,500 Shares for $2.94 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy MAZE?
Source: NASDAQ.COM
- Insider Transaction: Atul Dandekar, Chief Strategy Officer of Maze Therapeutics, exercised 72,500 shares and immediately sold them for approximately $2.94 million, indicating a strategic liquidity management approach during the clinical stage.
- Option Exercise: The transaction was executed at a weighted average purchase price of $40.56 as per SEC Form 4, suggesting that Dandekar's sale does not alter the company's strategic outlook.
- Financial Position: Maze Therapeutics reported $383.9 million in cash and marketable securities at the end of Q3, providing sufficient runway to fund operations into 2028, highlighting its financial stability for upcoming clinical trials.
- Market Reaction: Although Dandekar's direct holdings decreased by approximately 87%, Maze's stock surged 150% over the past year, reflecting investor optimism regarding the company's future clinical trial outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.180
Low
46.00
Averages
52.00
High
60.00
Current: 44.180
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
a16z Capital Management Acquires Navan Shares
- New Investment Highlight: According to the SEC filing dated February 17, 2026, a16z Capital Management acquired approximately 27 million shares of Navan in Q4 2025, with an estimated transaction value of $464.5 million, indicating strong confidence in Navan's future growth potential.
- Asset Allocation Shift: This acquisition positions Navan as 29.4% of a16z's reportable assets under management, reflecting its significant importance in the investment portfolio and potentially influencing future investment strategies.
- Market Performance Analysis: As of December 31, 2025, Navan's share price was $9.97, with a current market price of $10.23 and a market capitalization of $2.54 billion, showcasing market recognition of its technology-driven enterprise spend management platform.
- Business Model Transformation: Navan has evolved from a traditional travel booking tool to a comprehensive enterprise spend platform, integrating travel, payments, and expense management, thereby enhancing cost control and operational efficiency for businesses, attracting increased attention from corporate clients.
See More
a16z Capital Management Acquires Navan Shares
- New Investment Scale: a16z Capital Management acquired 27,195,364 shares of Navan in Q4 2025, with an estimated transaction value of $464.50 million, significantly enhancing the diversity of its asset portfolio.
- Asset Proportion Increase: Navan now accounts for 29.4% of a16z Capital Management's 13F reportable assets, making it the fund's second-largest holding, reflecting confidence in Navan's future growth potential.
- Technology-Driven Business Model: Navan focuses on software solutions for enterprise travel and expense management, leveraging artificial intelligence to enhance operational efficiency and help companies achieve cost control, thereby strengthening its competitive position in the market.
- Diversified Revenue Sources: Navan generates revenue from software subscriptions and payment transaction processing, providing a dual revenue model that ensures future financial stability while increasing its significance in enterprise spend management.
See More
Maze Therapeutics Executive Sells Stock Options
- Executive Transaction Overview: Harold Bernstein, President of R&D at Maze Therapeutics, exercised 15,000 options on February 2, 2026, and sold the shares in an open-market transaction valued at approximately $690,300, fully divesting his direct ownership, which reflects executive confidence in the company's future.
- Transaction Structure Analysis: This was a derivative transaction involving the exercise of 15,000 stock options followed by an immediate sale of the resulting shares, illustrating Bernstein's decision-making process that reduced his holdings from 90,000 shares to zero over the past year through a series of administrative transactions.
- Investor Impact Assessment: Although Bernstein no longer holds direct shares, he retains nearly 300,000 stock options, and this transaction was part of a 10b5-1 trading plan, indicating that the sale does not reflect a negative outlook on the company, alleviating investor concerns.
- Market Performance Review: Since its IPO on January 31, 2025, Maze Therapeutics has achieved a 158% annual increase in stock price within four months post-listing, and while a brief pullback may occur, Wall Street analysts widely consider the stock a strong buy as it continues to advance in clinical trials for multiple medicines.
See More
Maze Therapeutics Executive Sells Shares
- Executive Stock Transaction: On February 2, 2026, Maze Therapeutics' Chief Medical Officer Harold Bernstein exercised 15,000 options and sold them immediately for approximately $690,300, indicating executive confidence in the company's future prospects.
- Strong Market Performance: Celebrating its one-year anniversary, Maze Therapeutics has seen a 174% stock price increase over the past year, with a remarkable 158% rise in the first four months of 2025, reflecting strong demand for its products and positive investor sentiment.
- Change in Shareholding Structure: Although Bernstein divested all his direct shares, he retains nearly 300,000 stock options, suggesting ongoing confidence in the company's future and that he has not fully exited his investment.
- Analyst Perspectives: While Maze Therapeutics was not included in the current top investment stocks by The Motley Fool Stock Advisor, Wall Street analysts generally consider it a strong buy, indicating optimism regarding its progress in clinical trials.
See More
Analysis of Maze Therapeutics Executive Stock Transaction
- Executive Stock Transaction: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them on January 22, 2026, for approximately $227,612, indicating proactive management of executive stock holdings.
- Ownership Change: Following the transaction, Bachrodt's direct holdings decreased to 12,965 shares, representing 0.0269% of Maze Therapeutics' outstanding shares, reflecting confidence in the company's future and risk management strategy.
- Compliance with Trading Plan: The stock sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to schedule trades in advance, ensuring compliance and transparency in the transaction.
- Market Performance Outlook: Since its IPO on January 31, 2025, Maze Therapeutics' stock surged 158% in 2025, and while it continues to rise in early 2026, investors should be cautious of potential short-term pullbacks, although the long-term outlook remains promising, particularly with advancements in clinical trials for kidney and metabolic diseases.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
a16z Capital Management Acquires Navan Shares
- New Investment Highlight: According to the SEC filing dated February 17, 2026, a16z Capital Management acquired approximately 27 million shares of Navan in Q4 2025, with an estimated transaction value of $464.5 million, indicating strong confidence in Navan's future growth potential.
- Asset Allocation Shift: This acquisition positions Navan as 29.4% of a16z's reportable assets under management, reflecting its significant importance in the investment portfolio and potentially influencing future investment strategies.
- Market Performance Analysis: As of December 31, 2025, Navan's share price was $9.97, with a current market price of $10.23 and a market capitalization of $2.54 billion, showcasing market recognition of its technology-driven enterprise spend management platform.
- Business Model Transformation: Navan has evolved from a traditional travel booking tool to a comprehensive enterprise spend platform, integrating travel, payments, and expense management, thereby enhancing cost control and operational efficiency for businesses, attracting increased attention from corporate clients.
See More
a16z Capital Management Acquires Navan Shares
- New Investment Scale: a16z Capital Management acquired 27,195,364 shares of Navan in Q4 2025, with an estimated transaction value of $464.50 million, significantly enhancing the diversity of its asset portfolio.
- Asset Proportion Increase: Navan now accounts for 29.4% of a16z Capital Management's 13F reportable assets, making it the fund's second-largest holding, reflecting confidence in Navan's future growth potential.
- Technology-Driven Business Model: Navan focuses on software solutions for enterprise travel and expense management, leveraging artificial intelligence to enhance operational efficiency and help companies achieve cost control, thereby strengthening its competitive position in the market.
- Diversified Revenue Sources: Navan generates revenue from software subscriptions and payment transaction processing, providing a dual revenue model that ensures future financial stability while increasing its significance in enterprise spend management.
See More
Maze Therapeutics Executive Sells Stock Options
- Executive Transaction Overview: Harold Bernstein, President of R&D at Maze Therapeutics, exercised 15,000 options on February 2, 2026, and sold the shares in an open-market transaction valued at approximately $690,300, fully divesting his direct ownership, which reflects executive confidence in the company's future.
- Transaction Structure Analysis: This was a derivative transaction involving the exercise of 15,000 stock options followed by an immediate sale of the resulting shares, illustrating Bernstein's decision-making process that reduced his holdings from 90,000 shares to zero over the past year through a series of administrative transactions.
- Investor Impact Assessment: Although Bernstein no longer holds direct shares, he retains nearly 300,000 stock options, and this transaction was part of a 10b5-1 trading plan, indicating that the sale does not reflect a negative outlook on the company, alleviating investor concerns.
- Market Performance Review: Since its IPO on January 31, 2025, Maze Therapeutics has achieved a 158% annual increase in stock price within four months post-listing, and while a brief pullback may occur, Wall Street analysts widely consider the stock a strong buy as it continues to advance in clinical trials for multiple medicines.
See More
Maze Therapeutics Executive Sells Shares
- Executive Stock Transaction: On February 2, 2026, Maze Therapeutics' Chief Medical Officer Harold Bernstein exercised 15,000 options and sold them immediately for approximately $690,300, indicating executive confidence in the company's future prospects.
- Strong Market Performance: Celebrating its one-year anniversary, Maze Therapeutics has seen a 174% stock price increase over the past year, with a remarkable 158% rise in the first four months of 2025, reflecting strong demand for its products and positive investor sentiment.
- Change in Shareholding Structure: Although Bernstein divested all his direct shares, he retains nearly 300,000 stock options, suggesting ongoing confidence in the company's future and that he has not fully exited his investment.
- Analyst Perspectives: While Maze Therapeutics was not included in the current top investment stocks by The Motley Fool Stock Advisor, Wall Street analysts generally consider it a strong buy, indicating optimism regarding its progress in clinical trials.
See More
Analysis of Maze Therapeutics Executive Stock Transaction
- Executive Stock Transaction: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them on January 22, 2026, for approximately $227,612, indicating proactive management of executive stock holdings.
- Ownership Change: Following the transaction, Bachrodt's direct holdings decreased to 12,965 shares, representing 0.0269% of Maze Therapeutics' outstanding shares, reflecting confidence in the company's future and risk management strategy.
- Compliance with Trading Plan: The stock sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to schedule trades in advance, ensuring compliance and transparency in the transaction.
- Market Performance Outlook: Since its IPO on January 31, 2025, Maze Therapeutics' stock surged 158% in 2025, and while it continues to rise in early 2026, investors should be cautious of potential short-term pullbacks, although the long-term outlook remains promising, particularly with advancements in clinical trials for kidney and metabolic diseases.
See More
